NO20061254L - Farmasoytiske blandinger - Google Patents

Farmasoytiske blandinger

Info

Publication number
NO20061254L
NO20061254L NO20061254A NO20061254A NO20061254L NO 20061254 L NO20061254 L NO 20061254L NO 20061254 A NO20061254 A NO 20061254A NO 20061254 A NO20061254 A NO 20061254A NO 20061254 L NO20061254 L NO 20061254L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
pharmaceutical mixtures
relates
airways
mucous
Prior art date
Application number
NO20061254A
Other languages
English (en)
Norwegian (no)
Inventor
John Nicholas Staniforth
David Morton
David Ganderton
Yorick Kamlag
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0321611.6A external-priority patent/GB0321611D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20061254L publication Critical patent/NO20061254L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20061254A 2003-09-15 2006-03-17 Farmasoytiske blandinger NO20061254L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0321611.6A GB0321611D0 (en) 2003-09-15 2003-09-15 Pharmaceutical compositions
GBGB0327723.3A GB0327723D0 (en) 2003-09-15 2003-11-28 Pharmaceutical compositions
PCT/GB2004/003932 WO2005025540A2 (fr) 2003-09-15 2004-09-15 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
NO20061254L true NO20061254L (no) 2006-04-11

Family

ID=34315438

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061254A NO20061254L (no) 2003-09-15 2006-03-17 Farmasoytiske blandinger

Country Status (15)

Country Link
US (2) US7928089B2 (fr)
EP (2) EP2277505A3 (fr)
JP (2) JP4913595B2 (fr)
KR (1) KR20060082865A (fr)
CN (1) CN1874757B (fr)
AU (1) AU2004271778B2 (fr)
BR (1) BRPI0414425A (fr)
CA (1) CA2538399A1 (fr)
GB (1) GB0327723D0 (fr)
IL (1) IL173987A0 (fr)
NO (1) NO20061254L (fr)
NZ (1) NZ545550A (fr)
RU (1) RU2363448C2 (fr)
SG (1) SG146649A1 (fr)
WO (1) WO2005025540A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CN1980694B (zh) * 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
KR20090060348A (ko) * 2006-09-19 2009-06-11 디스커버리 래보래토리스, 인크. 폐 계면활성제 제제 및 점액 클리어런스 촉진 방법
CN101433521B (zh) * 2007-11-14 2012-08-08 中国医学科学院药用植物研究所 药用可吸入微粒、使用其的肺部吸入制剂及其制备方法
EP2708603B1 (fr) 2008-01-25 2017-04-19 The General Hospital Corporation Utilisations diagnostiques et thérapeutiques de la gelsoline dans une insuffisance rénale
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2010102065A1 (fr) 2009-03-05 2010-09-10 Bend Research, Inc. Compositions pharmaceutiques de dérivés de polymère de dextrane
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
WO2012031133A2 (fr) 2010-09-03 2012-03-08 Bench Research, Inc. Appareil de séchage par atomisation et procédés d'utilisation de cet appareil
WO2012031129A2 (fr) 2010-09-03 2012-03-08 Bend Research, Inc. Appareil de séchage par pulvérisation et ses procédés d'utilisation
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012073025A1 (fr) * 2010-11-30 2012-06-07 Vectura Limited Glucosaminoglucanes, tels que l'héparine, en vue d'une utilisation dans le traitement d'une inflammation pulmonaire, telle que la maladie pulmonaire obstructive chronique (mpoc)
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
US20150045410A1 (en) * 2012-02-06 2015-02-12 University Of Iowa Research Foundation Method of regulating cftr expression and processing
SG11201407676VA (en) * 2012-05-21 2015-03-30 Agency Science Tech & Res A dry powder formulation
ITMI20121052A1 (it) * 2012-06-18 2013-12-19 Ecupharma Srl Formulazioni inalatorie per la rimozione delle secrezioni viscose dall'apparato respiratorio
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
HRP20260435T1 (hr) 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
SG11201702614SA (en) * 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
SG11201702688UA (en) 2014-10-10 2017-04-27 Ablynx Nv Methods of treating rsv infections
WO2016055655A1 (fr) * 2014-10-10 2016-04-14 Ablynx N.V. Dispositif d'inhalation pour utilisation dans une thérapie par aérosol de maladies respiratoires
CA2962719A1 (fr) 2014-10-31 2016-05-06 Bend Research Inc. Procede de formation de domaines actifs disperses dans une matrice
CN105920020B (zh) * 2016-06-23 2019-01-08 潘海英 一种治疗肺部疾病的药物组合物及其制备方法和用途
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
US11116722B2 (en) * 2016-10-14 2021-09-14 Pulmatrix Operating Company, Inc. Antifungal dry powders
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
TR201722950A2 (tr) * 2017-12-29 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Koah tedavisinde yeni farmasötik bileşimler.
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
CA3132400C (fr) * 2019-03-18 2026-05-12 Cedars-Sinai Medical Center Compositions et methodes pour traiter des maladies et des troubles gastro-intestinaux
US11413289B2 (en) 2019-05-16 2022-08-16 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
KR102250876B1 (ko) * 2019-07-18 2021-05-11 충북대학교 산학협력단 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물
WO2025034892A2 (fr) * 2023-08-07 2025-02-13 The University Of North Carolina At Chapel Hill Agent de contraste ultrasonore pour une liaison à un mucus respiratoire ou une adhérence à celui-ci et ses procédés d'utilisation

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734401A (en) * 1986-03-17 1988-03-29 W. R. Grace & Co. Process for spray drying amino acid compositions
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
DE69306379T2 (de) * 1992-03-10 1997-06-12 Fisons Plc Inhalierbare arzneimittel
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US5668118A (en) * 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
EP1164145B1 (fr) * 1992-07-24 2007-12-05 Thomas P. Kennedy Héparines désulfatées non anticoagulantes en tant que médicaments
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
ES2306452T3 (es) * 1995-10-17 2008-11-01 Jagotec Ag Aporte de farmacos insolubles.
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
DE69724420T2 (de) * 1996-04-29 2004-06-09 Quadrant Technologies Ltd. Verfahren zum inhalieren trockener pulver
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6001336A (en) * 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
CA2283705A1 (fr) * 1997-03-20 1998-10-01 Novo Nordisk A/S Cristaux d'insuline depourvus de zinc et utiles dans des compositions pour les voies respiratoires
US20010046974A1 (en) 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US6075013A (en) * 1997-06-06 2000-06-13 Hamilton Civic Hospitals Research Development Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CA2209342A1 (fr) 1997-06-30 1998-12-30 The University Of British Columbia Utilisation de dextrans et d'autres saccharides oligomeriques pour ameliorer le degagement des voies respiratoires
IT1296998B1 (it) 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
US20030118514A1 (en) 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
DK1165050T3 (da) 1999-04-05 2006-05-01 Mannkind Corp Fremgangsmåde til dannelse af fint pulver
WO2000061178A1 (fr) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6560897B2 (en) * 1999-05-03 2003-05-13 Acusphere, Inc. Spray drying apparatus and methods of use
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
HK1045532A1 (zh) 1999-06-30 2002-11-29 Hamilton Civic Hospitals Research Development, Inc. 抑制与凝结有关凝结因子的肝素成份
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
WO2001015672A2 (fr) 1999-08-26 2001-03-08 Governors Of The University Of Alberta Utilisation de dextrane comme agent mucoactif, methodes et compositions pharmaceutiques connexes
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
EP1129705A1 (fr) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Formulation en poudre pour inhalation
CA2340836A1 (fr) 2000-03-18 2001-09-18 Degussa Ag Produit granulaire
US6369115B1 (en) * 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US20050032745A1 (en) 2000-05-04 2005-02-10 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CN1197587C (zh) 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
ES2292598T3 (es) * 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
WO2002032406A2 (fr) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Procedes et produits associes a l'administration pulmonaires de polysaccharides
CN100400031C (zh) 2000-11-29 2008-07-09 伊藤火腿株式会社 粉末制剂及其制备方法
EP2283817B1 (fr) 2000-11-30 2016-05-18 Vectura Limited Procédé de préparation de particules destinées à être utilisées dans une composition pharmaceutique
US8580306B2 (en) 2000-11-30 2013-11-12 Vectura Limited Particles for use in a pharmaceutical composition
NZ526059A (en) 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
WO2002051389A2 (fr) * 2000-12-22 2002-07-04 Aspen Aerogels, Inc. Agents therapeutiques pulverulents d'aerogel
GB0102902D0 (en) 2001-02-06 2001-03-21 Innovata Biomed Ltd Medicaments
GB0106403D0 (en) 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10141376A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
EP1487417A4 (fr) 2001-09-17 2010-03-17 Glaxo Group Ltd Formulations de medicament en poudre seche
US20030091513A1 (en) 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
WO2003035028A1 (fr) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulation de la densite de charge pour ameliorer les caracteristiques de proteines sechees par pulverisation
US20050013867A1 (en) 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
EP1992335A1 (fr) 2001-11-01 2008-11-19 Nektar Therapeutics Procédés de séchage par pulvérisation et compositions correspondantes
BR0214280A (pt) 2001-11-19 2005-01-11 Becton Dickinson Co Composição farmacêuticas em forma particulada
WO2003043586A2 (fr) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions destinees a la liberation de produits a action continue
US20060188451A1 (en) 2001-12-21 2006-08-24 Aspen Aerogels, Inc. Aerogel based pharmaceutical formulations
US20030124087A1 (en) 2001-12-26 2003-07-03 Amitie Co. Ltd. Anti-adhesion barrier
WO2003068254A1 (fr) * 2002-02-18 2003-08-21 University Of Southampton Polytherapie a base de glycosaminoglycane-dnase
ES2565028T3 (es) 2002-02-18 2016-03-30 Ockham Biotech Limited Terapia de combinación para trastornos respiratorios
PT1511466E (pt) * 2002-02-18 2009-01-16 Ockham Biotech Ltd Utilização de glicosaminoglicanos tais como heparina para o tratamento de desordens respiratórias tais como dpoc
WO2003072080A1 (fr) * 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Formulations inhalables destinees a une liberation prolongee
FI116657B (fi) 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
EP1494652A1 (fr) 2002-04-12 2005-01-12 Campina Nederland Holding B.V. Excipient destine a des preparations d'inhalation de poudre seche
EP1531795A4 (fr) 2002-05-02 2011-02-23 Harvard College Formulations limitant l'extension d'infections pulmonaires
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US20040028746A1 (en) 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US20040043064A1 (en) 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
GB0304540D0 (en) 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
US6933372B2 (en) * 2003-03-07 2005-08-23 Warner-Lambert Company Method to produce a solid form of heparin
WO2005000267A2 (fr) 2003-05-28 2005-01-06 Nektar Therapeutics Produit pharmaceutique formule comprenant un principe actif insoluble dans l'eau
CA2435632A1 (fr) 2003-07-21 2005-01-21 Warren Hugh Finlay Preparation en poudre contenant des nanoparticules pour liberation dans les poumons sous forme d'aerosol
WO2005009375A2 (fr) 2003-07-22 2005-02-03 Baxter International Inc. Petites particules spheriques de molecules organiques de faible poids moleculaire et procedes de preparation et d'utilisation correspondants
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
PL1699434T3 (pl) 2003-09-02 2011-09-30 Norton Healthcare Ltd Sposób wytwarzania leku
EP1663164A2 (fr) * 2003-09-15 2006-06-07 Vectura Limited Procedes de preparation de compositions pharmaceutiques
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US7560444B2 (en) * 2003-10-01 2009-07-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
CN1261105C (zh) * 2003-12-05 2006-06-28 吉林省辽源亚东药业股份有限公司 一种复方吡拉西坦脑蛋白水解物制剂及制备方法
GB0329208D0 (en) 2003-12-17 2004-01-21 Ici Plc Particulate materials
EP1697034A1 (fr) 2003-12-23 2006-09-06 Niro A/S Procede et appareil pour produire des microparticules
US7928059B2 (en) * 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
EP2165711B1 (fr) * 2004-05-27 2014-05-21 Baxter International Inc. Procédé pour traiter des troubles du saignement à l'aide de polysaccharides sulfatés
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006033693A2 (fr) 2004-06-30 2006-03-30 Deangelis Paul L Procedes de traitement selectif de maladies par des polymeres de glycosaminoglycane specifiques
WO2006019894A2 (fr) * 2004-07-14 2006-02-23 O'connor Michael F Compositions pharmaceutiques pulverisees pour le traitement de troubles bronchiques
GB0416397D0 (en) 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP1789018A1 (fr) 2004-08-27 2007-05-30 The Dow Chemical Company Administration amelioree de compositions medicamenteuses pour le traitement d'infections parfois mortelles
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
CA2601969A1 (fr) 2005-02-10 2006-08-17 Orexo Ab Nouvelles compositions pharmaceutiques utiles pour l'administration transmuqueuse de medicaments
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
CN101312713A (zh) 2005-03-18 2008-11-26 纳米材料科技有限公司 可吸入的药物
CA2606861C (fr) 2005-05-05 2012-08-07 Sanofi-Aventis U.S. Llc Formulations nanoparticulaires stables
US20080306022A1 (en) 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
US20070098803A1 (en) 2005-10-27 2007-05-03 Primet Precision Materials, Inc. Small particle compositions and associated methods
US7597094B2 (en) * 2005-11-29 2009-10-06 Leon Monroe Pittman Compound bow maintenance press and method for compressing a compound bow from the bow limb ends
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
CA2633254A1 (fr) 2005-12-16 2007-07-05 Tap Pharmaceutical Products, Inc. Compositions pharmaceutiques d'ilaprazole
DE102005062270A1 (de) 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
US20070166386A1 (en) 2006-01-13 2007-07-19 Chinea Vanessa I Nanoparticle formation of pharmaceutical ingredients
RU2008142388A (ru) 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) Микрочастицы лекарственного вещества
CA2648291A1 (fr) 2006-04-04 2007-11-01 Stc.Unm Particules gonflantes pour l'administration d'un medicament
WO2008054508A2 (fr) 2006-04-13 2008-05-08 Alza Corporation Médicament amorphe stable de taille nanométrique
WO2008002485A2 (fr) 2006-06-23 2008-01-03 Alza Corporation Stabilité amorphe améliorée de médicaments peu solubles dans l'eau par mise à taille nanométrique
WO2008011051A1 (fr) 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Procédés, systèmes et matériaux de fabrication de nanoparticules
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP1944018A1 (fr) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
US20090203789A1 (en) * 2008-01-31 2009-08-13 Multi Formulations Ltd. Fast Dissolution Amino Acid Composition

Also Published As

Publication number Publication date
CN1874757A (zh) 2006-12-06
AU2004271778B2 (en) 2011-04-21
JP2012031204A (ja) 2012-02-16
EP2277505A3 (fr) 2011-06-15
JP2007505830A (ja) 2007-03-15
AU2004271778A1 (en) 2005-03-24
SG146649A1 (en) 2008-10-30
GB0327723D0 (en) 2003-12-31
RU2363448C2 (ru) 2009-08-10
WO2005025540A2 (fr) 2005-03-24
KR20060082865A (ko) 2006-07-19
EP2277505A2 (fr) 2011-01-26
CN1874757B (zh) 2011-03-09
WO2005025540A3 (fr) 2005-06-16
US20110217339A1 (en) 2011-09-08
RU2006112583A (ru) 2007-11-10
CA2538399A1 (fr) 2005-03-24
IL173987A0 (en) 2006-07-05
US7928089B2 (en) 2011-04-19
US20070065373A1 (en) 2007-03-22
BRPI0414425A (pt) 2006-11-14
NZ545550A (en) 2009-03-31
EP1663151A2 (fr) 2006-06-07
JP4913595B2 (ja) 2012-04-11

Similar Documents

Publication Publication Date Title
SG146649A1 (en) Mucoactive agents for treating a pulmonary disease
SE0200356D0 (sv) Novel use
NO20024708L (no) Behandling av respiratoriske sykdommer
NO20070994L (no) N-hydroksamid derivater og anvendelse derav
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
MXPA02011311A (es) Composicion novedosa.
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
NO20070987L (no) Polysulfaterte glykosider og salter av disse.
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
WO2004043392A3 (fr) Inhibiteurs de synthese de la mucine
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
TW200720236A (en) Organic compounds
DK1406667T3 (da) Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
NO20065757L (no) Purinderivater
WO2004113286A3 (fr) Inhibiteurs de la synthese des mucines
NO20070820L (no) Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
ZA200704921B (en) Sulfonyl amino cyclic derivatives and use thereof
NO20074458L (no) N-hydroksamidderivater og anvendelse derav
WO2007046113A3 (fr) Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede
ATE413187T1 (de) Pharmazeutische zusammensetzungen mit interferon- tau
UA88785C2 (en) N-hydroxyamide derivatives and use thereof
NO20073633L (no) Sulfonylamino sykliske derivater og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application